Diabetic nephropathy: protective factors and a new therapeutic paradigm

• Published in: Journal of diabetes and its complications Vol. 27; no. 5; pp. 526 - 530
• Main Author: Mima, Akira
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.09.2013; Elsevier Limited
• Subjects: Angiopoietins; Animals; Cytoprotection - drug effects; Cytoprotection - physiology; Diabetes; Diabetic Nephropathies - prevention & control; Diabetic Nephropathies - therapy; Diabetic nephropathy (DN); Dipeptidyl peptidase-4 (DPP-4) inhibitors; Dipeptidyl-Peptidase IV Inhibitors - pharmacology; Dipeptidyl-Peptidase IV Inhibitors - therapeutic use; Endocrinology & Metabolism; Endostatin; Glucagon like peptide-1 (GLP-1); Glucagon-Like Peptide 1 - physiology; Heme Oxygenase-1 - physiology; Humans; Hyperglycemia; Hypoglycemic Agents - therapeutic use; Insulin; Insulin - pharmacology; Insulin - therapeutic use; Insulin receptor substrate 1 (IRS1); Insulin resistance; Kidney - drug effects; Kidney - physiology; Kinases; Muscular system; Protein kinase C (PKC); Src homology-2 domain containing phosphatase-1 (SHP-1); Tumstatin; Vascular endothelial growth factor (VEGF); Vascular Endothelial Growth Factor A - physiology; Japan; Insulin receptor substrate 1 (IRS1); Diabetic nephropathy (DN); Dipeptidyl peptidase-4 (DPP-4) inhibitors; Vascular endothelial growth factor (VEGF); Endostatin; Tumstatin; Angiopoietins; Glucagon like peptide-1 (GLP-1); Insulin; Src homology-2 domain containing phosphatase-1 (SHP-1); Protein kinase C (PKC)
• ISSN: 1056-8727; 1873-460X
• DOI: 10.1016/j.jdiacomp.2013.03.003

Abstract Diabetic nephropathy (DN) is the most common cause of chronic kidney disease (CKD) and its number has been increasing. CKD is a worldwide threat to health but the precise mechanism of this problem is not fully appreciated. It is believed that hyperglycemia is one of the most important metabolic factors in the development of DN. Multiple molecular mechanisms have been proposed to mediate hyperglycemia’s adverse effects on kidney. To identify targets for therapeutic intervention, most studies have focused on understanding how abnormal levels of such metabolities cause DN. However, there have been few reports regarding endogenous renal protective factors. Thus, recognition of the importance of this could be providing a new perspective for understanding the development of DN and a new therapeutic paradigm to combat DN.